AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21667097
Drug: Overall follow-up
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall follow-up after ablative treatment
Trial: 16131698
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C supplementation (500 or 1000 mg/d for 2 weeks)
Trial: 7666815
Drug: Hormone Replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone Replacement Therapy (HRT) - either peroral or transdermal 17‐beta‐oestradiol with cyclic addition of dydrogesterone or 2.5 mg Tibolone (Org OD 14) in a daily peroral dose
Trial: 326302
Drug: Atenolol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (50 mg) and Acetazolamide (500 mg) in combination
Trial: 326302
Drug: Vehicle (inert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle (inert tablets)
Trial: 27866187
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein supplementation (24 g PRO)
Trial: 27866187
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein plus creatine supplementation (24 g PRO + 5 g creatine)
Trial: 22944053
Drug: tianmaixiaoke tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tianmaixiaoke tablet 240 mg bid for 24 weeks
Trial: 22944053
Drug: sitagliptin 100
RxNorm normalized name: SITagliptin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sitagliptin 100 mg qd for 24 weeks
Trial: 16417772
Drug: Qingqiao Capsule
DrugBank: Forsythia suspensa fruit (DB14345)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qingqiao Capsule (QQC), 5 capsules each time, 3 times a day for 10-14 days
Trial: 16417772
Drug: Cefaclor capsules,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefaclor capsules, 0.5 g each time for adults, 3 times a day, or 20 mg/(kg.d) for children, for 10-14 days
Trial: 16417772
Drug: Qingqiao Capsule
DrugBank: Forsythia suspensa fruit (DB14345)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qingqiao Capsule (QQC)
Trial: 16417772
Drug: Cefaclor capsules
RxNorm normalized name: Cefaclor Capsules
DrugBank: Cefaclor (DB00833)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefaclor capsules
Trial: 12854076
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of CM235 and SF2 gp120 vaccines
Trial: 2016618
Drug: Chlorambucil (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorambucil (30 mg/m2 orally day 1) and Prednisone (80 mg orally days 1 to 5) administered every 2 weeks (C + P)
Trial: 2016618
Drug: Cyclophosphamide (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide (300 mg/m2 orally days 1 to 5), Vincristine (1.4 mg/m2 intravenously [IV] day 1), and Prednisone (100 mg/m2 orally days 1 to 5) given every 3 weeks (CVP)
Trial: 31810741
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no periodontal treatment)
Trial: 29912799
Drug: Aripiprazole (5-15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole (5-15 mg/d)
Trial: 27344828
Drug: Float needle
RxNorm normalized name: NEEDLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Float needle therapy combined with reperfusion activity
Trial: 27344828
Drug: Simple float
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simple float needle therapy
Trial: 24939425
Drug: Coinfusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coinfusion of low-dose GLP-1 and glucagon
Trial: 17561350
Drug: Taxane treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taxane treatment arm
Trial: 16205932
Drug: Choline-stabilized orthosilicic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Choline-stabilized orthosilicic acid (ch-OSA) 10 mg Si/day for 20 weeks
Trial: 12885182
Drug: Fentanyl 50
RxNorm normalized name: fentanyl 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 50 mcg/kg (group F)
Trial: 12885182
Drug: Fentanyl 10
RxNorm normalized name: FENTANYL 100MCG/HR PATCH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 10 mcg/kg plus etomidate 0.2 mg/kg (group EF)
Trial: 9322520
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of lamivudine
Trial: 9322520
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg of lamivudine
Trial: 8135383
Drug: 2% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lidocaine topical solution
Trial: 105441
Drug: Superfractionation treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Superfractionation treatment
Trial: 28752209
Drug: Extended-release nicotinic
RxNorm normalized name: nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extended-release nicotinic acid (ERN) 2 g/day for 8 weeks
Trial: 22035508
Drug: High-dose pirfenidone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose pirfenidone (1800 mg/day)
Trial: 22035508
Drug: Low-dose pirfenidone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose pirfenidone (1200 mg/day)
Trial: 16735334
Drug: Curtains treated
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Curtains treated with lambdacyhalothrin and water treatment with pyriproxyfen chips in Veracruz
Trial: 15332694
Drug: Pharmacist surveillance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist surveillance for adverse drug events (ADEs)
Trial: 15332694
Drug: Pharmacist surveillance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist surveillance for drug classes associated with ADEs
Trial: 9283534
Drug: Nocturnal CPAP
RxNorm normalized name: Nocdurna
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Nocturnal CPAP plus optimal medical therapy (n = 9)
Trial: 9283534
Drug: Optimal medical
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal medical therapy alone (n = 8)
Trial: 3324520
Drug: Febuprol (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Febuprol (3 X 200 mg t. i. d.)
Trial: 28862770
Drug: Oral glucosamine
RxNorm normalized name: glucosamine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucosamine (GS) + hyaluronic acid (HA) injection
Trial: 28862770
Drug: Oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo + hyaluronic acid (HA) injection
Trial: 26777773
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy (CBT) as an adjunct to usual care (medication)
Trial: 26777773
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (medication)
Trial: 22553931
Drug: l-arginine (6.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-arginine (6.4 g/day)
Trial: 18008242
Drug: Sulfadoxine‐pyrimethamine (SP;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfadoxine‐pyrimethamine (SP; 250 and 12.5 mg)
Trial: 16166818
Drug: 300 ml
RxNorm normalized name: HYQVIA 30 GM / 300 ML Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 ml wine from one of four different grapes and fermentation processes
Trial: 10907623
Drug: 900 mg
RxNorm normalized name: diosmin 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg magnesium citrate twice daily for 1 month
Trial: 6208750
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy (cis-platinum, bleomycin, and vinblastine)
Trial: 6208750
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus irradiation
Trial: 28143529
Drug: Individualized, computerized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized, computerized patient decision-aid for immunosuppressive drugs
Trial: 28143529
Drug: Standard pamphlet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard pamphlet with information about lupus and its treatment
Trial: 25932553
Drug: Emixustat (2,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emixustat (2, 5, 7, or 10 mg once daily)
Trial: 23545911
Drug: Extended-release 45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release 45 mg oral minocycline
Trial: 23545911
Drug: Extended-release 45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release 45 mg oral minocycline plus 15% azelaic acid
Trial: 18226251
Drug: Inhaled corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroid use
Trial: 16413877
Drug: Iron (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron (12.5 mg) and folic acid (50 mug)
Trial: 12409968
Drug: MCG QRS‐T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCG QRS‐T area integrals and QRS‐T angle in magnetic field maps
Trial: 9825256
Drug: New topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New topical therapies
Trial: 9825256
Drug: New treatments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New treatments that control IOP effectively over time
Trial: 7907677
Drug: Warfarin (prothrombin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (prothrombin time ratio 1.3‐1.8, international normalised ratio 2.0‐4.5)
Trial: 2811069
Drug: Nitrendipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine (20 mg) administered twice daily for five days
Trial: 2811069
Drug: Bumetanide (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bumetanide (1 mg, i.v.) administered for the last three days of each period
Trial: 2811069
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered twice daily for five days
Trial: 4037
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg terbutaline sulfate (beta‐adrenoceptor stimulating compound)
Trial: 10085709
Drug: Hemodialysis treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemodialysis treatment
Trial: 29752828
Drug: Cigarettes containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cigarettes containing 20 mg of THC
Trial: 27032659
Drug: Person-centered treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Person-centered treatment planning (Control)
Trial: 24365986
Drug: Tac (twice-daily)
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tac (twice-daily)
Trial: 24365986
Drug: TacMR (once-daily)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TacMR (once-daily)
Trial: 24365986
Drug: Tac (twice-daily)
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tac (twice-daily) after switching back
Trial: 20584695
Drug: Self-prescribed decoction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-prescribed decoction eliminating herpes combined with recombinant IL-2 and valaciclovir hydrochloride tablets
Trial: 20584695
Drug: Recombinant IL-2
RxNorm normalized name: Human il-12 (recombinant)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant IL-2 and valaciclovir hydrochloride tablets
Trial: 18676527
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose of American ginseng extract
Trial: 18676527
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of American ginseng extract
Trial: 12971959
Drug: Prophylactic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic therapy (specifics not detailed)
Trial: 12971959
Drug: No prophylactic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No prophylactic therapy (control group)
Trial: 10395842
Drug: Canarypox vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canarypox vaccine expressing multiple HIV-1 genes given alone or with rgp120
Trial: 10395842
Drug: Canarypox vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canarypox vaccine expressing multiple HIV-1 genes given with rgp120
Trial: 8618110
Drug: Cefetamet-pivoxil (CET,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefetamet-pivoxil (CET, 500 mg BID)
Trial: 8618110
Drug: Cefixime (CFX,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefixime (CFX, 400 mg qD)
Trial: 8618110
Drug: Cefuroxime axetil
RxNorm normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefuroxime axetil (CA, 250 mg BID)
Trial: 2405523
Drug: Cefmetazole (CM)
RxNorm normalized name: Cefmetazole
DrugBank: Cefmetazole (DB00274)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefmetazole (CM) 1 gram IV every 8 hours for 3 doses starting 30 minutes before surgery
Trial: 2405523
Drug: Cefoxitin (CX)
DrugBank: Cefoxitin (DB01331)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefoxitin (CX) 2 grams IV every 6 hours for 3 doses
Trial: 23110444
Drug: Ibuprofen foam
RxNorm normalized name: ibuprofen Topical Foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen foam dressing
Trial: 23110444
Drug: Comparator foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator foam dressing without ibuprofen
Trial: 20504911
Drug: Valsartan (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan (240 to 320 mg.day(‐1))
Trial: 20504911
Drug: Bradykinin B2-type
RxNorm normalized name: adenovirus, type 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bradykinin B2-type receptor antagonist icatibant (50 mug.kg(‐1))
Trial: 17646507
Drug: Liberal fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liberal fluid management (median 4250 mL, range 3150-5200 mL)
Trial: 17646507
Drug: Restrictive fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive fluid management (median 1740 mL, range 1100-2165 mL)
Trial: 15810473
Drug: Oral-B CrossAction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral-B CrossAction Vitalizer toothbrush
Trial: 11763941
Drug: Oral-B CrossAction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral-B CrossAction toothbrush
Trial: 15810473
Drug: Oral-B Advantage
RxNorm normalized name: Advantage Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral-B Advantage toothbrush
Trial: 6110088
Drug: Vaccine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine (3 monthly injections)
Trial: 6110088
Drug: Placebo (corresponding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (corresponding injections)
Trial: 26368296
Drug: Mesalamine granules
RxNorm normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mesalamine granules 1.5 g once daily for 6 months
Trial: 20930279
Drug: High-dose phenserine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose phenserine (10 and 15 mg BID)
Trial: 20930279
Drug: High-dose phenserine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose phenserine (more than 12 weeks)
Trial: 20930279
Drug: High-dose phenserine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose phenserine (after 12 weeks)
Trial: 16361622
Drug: Docetaxel 85
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 85 mg/m2 on day 8 plus gemcitabine 800 mg/m2 on days 1 and 8 (arm A)
Trial: 16361622
Drug: Docetaxel 75
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75 mg/m2 on day 1 plus cisplatin 75 mg/m2 on day 1 (arm B)
Trial: 10379016
Drug: Soybean oil
RxNorm normalized name: Soybean Oil
DrugBank: Soybean oil (DB09422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soybean oil diet (0.5 g trans fatty acid per 100 g)
Trial: 10379016
Drug: Semiliquid margarine
RxNorm normalized name: MARGARINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semiliquid margarine diet (0.5 g trans fatty acid per 100 g)
Trial: 10379016
Drug: Soft margarine
RxNorm normalized name: Soft margarine not polyunsaturated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soft margarine diet (7.4 g trans fatty acid per 100 g)
Trial: 10379016
Drug: Shortening diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shortening diet (9.9 g trans fatty acid per 100 g)
Trial: 10379016
Drug: Stick margarine
RxNorm normalized name: Zit Stick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stick margarine diet (20.1 g trans fatty acid per 100 g)
Trial: 2436423
Drug: 1% 11a-hydroxyprogesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% 11a-hydroxyprogesterone lotion
Trial: 31721143
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg oral micronized progesterone, six-hourly, starting at 14-18 weeks
Trial: 25342408
Drug: Doppler-guided goal-directed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doppler-guided goal-directed fluid therapy
Trial: 20576734
Drug: Intensive communication
RxNorm normalized name: cocklebur pollen extract
DrugBank: Xanthium strumarium pollen (DB10356)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive communication system (ICS) with family meetings within 5 days of ICU admission and weekly thereafter
Trial: 18004131
Drug: GHB (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHB (40 or 60 mg/kg)
Trial: 12062456
Drug: Amantadine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amantadine (100 mg bid)
Trial: 10202741
Drug: Transdermal 17-beta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal 17-beta estradiol 50 micrograms/d
Trial: 10202741
Drug: Ossein-hydroxyapatite compound
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ossein-hydroxyapatite compound 3.32 g/d
Trial: 10202741
Drug: Transdermal 17-beta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal 17-beta estradiol 50 micrograms/d plus Ossein-hydroxyapatite compound 3.32 g/d
Trial: 1771100
Drug: Etozolin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etozolin (200 mg, 400 mg, 600 mg)
Trial: 1771100
Drug: Chlorthalidone (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone (25 mg, 50 mg, 75 mg)
Trial: 9007884
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine (10 mg)
Trial: 17619868
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine (10 mg)
Trial: 24916838
Drug: Subcutaneous (SQ)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SQ) insulin
Trial: 23350696
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) insulin
Trial: 21457235
Drug: MAP0004 (0.63
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAP0004 (0.63 mg emitted dose; 1.0 mg nominal dose)
Trial: 17359519
Drug: No additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No additional therapy (Group C)
Trial: 11511435
Drug: Cardiac resynchronisation
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac resynchronisation therapy (atrio-bi-ventricular)
Trial: 11511435
Drug: Control (optimal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (optimal medical therapy with diuretics, ACE inhibitors, and beta-blockers)
Trial: 9612361
Drug: Drug-free treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-free treatment (Control)
Trial: 2694740
Drug: Gestrinone (2.5-5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gestrinone (2.5-5 mg, orally or by vaginal pessary, two or three times weekly)
Trial: 17603225
Drug: Glimepiride 2
RxNorm normalized name: glimepiride 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride 2 mg once-daily
Trial: 17603225
Drug: Glimepiride 1
RxNorm normalized name: glimepiride 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride 1 mg twice-daily
Trial: 17603225
Drug: Glimepiride 2
RxNorm normalized name: glimepiride 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride 2 mg once-daily and 1 mg twice-daily
Trial: 3075109
Drug: Ranitidine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (150 mg twice a day for 5 weeks)
Trial: 29231584
Drug: Granisetron hydrochloride
RxNorm normalized name: Granisetron Hydrochloride
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Granisetron hydrochloride injection, 3 mg before and after cisplatin chemotherapy, for 3 days
Trial: 29231584
Drug: Granisetron hydrochloride
RxNorm normalized name: Granisetron Hydrochloride
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Granisetron hydrochloride injection
Trial: 26186566
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses of cholecalciferol
Trial: 21903745
Drug: Sequential chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential chemotherapy with cisplatin (100 mg/m2 on days 1 and 29, vinblastine at 5 mg/m2 per week for 5 weeks) and TRT (63 Gy delivered as once-daily fractions beginning on day 50)